SNMMI
SNMMI
Advertisement
Kerri FitzgeraldSNMMI | April 23, 2023
Piflufolastat F 18 is a radiopharmaceutical that targets the prostate-specific membrane antigen during imaging.
Read More
Kerri FitzgeraldSNMMI | August 9, 2022
This model assigns workers to additional or alternate roles that match existing skills and providing proper re-training.
Kerri FitzgeraldSNMMI | August 9, 2022
Researchers retrospectively analyzed patients who had received both 68Ga-PSMA PET/CT and mpMRI testing.
Kerri FitzgeraldSNMMI | September 21, 2023
The approach may help inform clinical decision-making early in treatment.
Kerri FitzgeraldSNMMI | August 9, 2022
Updates may be needed to guidelines for salvage radiation treatments in patients with local recurrence of prostate ...
Kerri FitzgeraldSNMMI | August 9, 2022
Developers and users must be aware of the potential for data attacks and manipulation when considering AI models for ...
Kerri FitzgeraldSNMMI | August 24, 2023
The authors of the study won the 2022 SNMMI Abstract of the Year Award.
Kerri FitzgeraldSNMMI | June 30, 2023
The novel artificial intelligence can produce high-quality PET/CT images while decreasing radiation exposure to ...
Kerri FitzgeraldSNMMI | August 9, 2022
Researchers conducted a prospective phase 2 imaging study to compare PSMA and GRP-R-targeted imaging during initial ...
Kerri FitzgeraldSNMMI | August 9, 2022
Guided imagery can enhance coping, reduce anxiety, and decrease heart rate, respirations, and blood pressure.
Kerri FitzgeraldSNMMI | August 9, 2022
A study explore values of parametric Ki imaging in total-body 68Ga-PSMA-11 PET/CT in patients with prostate cancer.
Kerri FitzgeraldSNMMI | April 11, 2023
The framework emphasizes the importance of establishing trust among stakeholders.
Kerri FitzgeraldSNMMI | April 23, 2023
The study is the first to show that lingering COVID-19 symptoms can be attributed to ongoing lung inflammation.
Advertisement
Advertisement
Advertisement
Latest News

April 19, 2024